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Abstract:  1 
Intervertebral disc degeneration is characterised by an imbalance between catabolic and 2 
anabolic signalling, with an increase in catabolic cytokines particularly IL-1β, a key regulator 3 
of IVD degeneration. This study aimed to investigate intracellular signalling pathways 4 
activated by IL-1β, and GDF-5 in the degenerate IVD to identify potential new therapeutic 5 
targets.  6 
Human NP cells were cultured in alginate beads to regain in vivo phenotype prior to 7 
stimulation with IL-1β or GDF-5 for 30 minutes, a proteasome profiler array was initially 8 
utilised to screen activation status of 46 signalling proteins. Immunoflourescence was used 9 
to investigate activation of the NFB pathway. Cell based ELISAs were then deployed to 10 
confirm results for ERK1/2, p38 MAPK, c-jun and IB signalling. IHC was utilised to 11 
investigate native activation status within human IVD tissue between grades of 12 
degeneration. Finally cells were stimulated with IL-1β in the absence or presence of p38 13 
MAPK, c-jun, JNK and NFB inhibitors to investigate effects on MMP3, MMP13, IL-1β, IL-6 14 
and IL-8 mRNA expression.  15 
This study demonstrated three key signalling pathways which were differentially activated by 16 
IL-1β but not GDF-5; namely p38 MAPK, c-jun and NFB. Whilst ERK 1/2 was activated by 17 
both GDF-5 and IL-1. Immunohistochemistry demonstrated p38 MAPK, c-jun and NFB 18 
were activated during human IVD degeneration and inhibition of these pathways reduced or 19 
abrogated the catabolic effects of IL-1β, with inhibition of NFB signalling demonstrating 20 
most widespread inhibition of IL-1β catabolic effects.  21 
  22 
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Introduction:  1 
The intervertebral disc (IVD) is an important component of the spinal column enabling 2 
bending, flexion and torsion of the spine, composed of the cartilaginous end plates (CEP), 3 
the annulus fibrosus (AF) and the central gelatinous nucleus pulposus (NP). The major 4 
components are water, collagens, proteoglycans, non-collagenous proteins and elastins. 5 
The collagen fibres of the IVD provide a strong durable framework supporting the cells and 6 
confine the highly hydrated proteoglycan aggregates1. The normal human IVD contains 7 
chondrocyte-like cells within the NP and inner AF termed NP and AF cells, and fibroblast-like 8 
cells in the outer AF. These cells are responsible for the synthesis and regulation of the 9 
matrix in the disc and control the homeostasis between extracellular matrix (ECM) synthesis 10 
and ECM degradation2. Within the normal adult IVD the anabolic and catabolic processes 11 
which regulate the ECM are thought to be kept in balance by a number of growth factors 12 
(e.g. TGF, FGF, IGF, GDF) and cytokines (e.g. IL-1, IL-6, IL-8, TNF) 3-5. If this balance is 13 
disrupted in favour of catabolic processes, the IVD begins to degrade, resulting in disc 14 
degeneration which can lead to low back pain (LBP)3. An improved understanding of the 15 
homeostatic mechanisms and those seen during degeneration of the disc are crucial to 16 
understanding the biology of this important tissue.  17 
Increasing data suggests that inflammatory cytokines produced by NP cells within the IVD 18 
during degeneration are responsible for matrix degradation and induction of painful stimuli6-19 
12
, with a particular role for IL-1β hypothesized6, 7, 9-11. IL-1β has been shown to be increased 20 
in degenerate IVDs without a concordant increase in its antagonist (IL-1Ra)6. IL-1β has also 21 
been shown to regulate a pleathora of events linked to IVD degeneration such as increased 22 
matrix degradation, decreased matrix synthesis, increased pro inflammatory cytokine 23 
production and increased production of neurotrophic and angiogenic factors6-10. 24 
Spontaneous degeneration was seen in a mouse model where the natural inhibitor of IL-1β 25 
(IL-1Ra) was knocked out11, which together with increased risks of LBP in patients with IL-1β 26 
polymorphisms13-16, suggests a major role for IL-1β in the pathogenesis of disc degeneration. 27 
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A number of methods to inhibit the catabolic processes (e.g. matrix degradation via TIMPs) 1 
have been proposed, however whilst these have shown some promise, many target 2 
individual catabolic cytokines (e.g. IL-1, TNF), which carries a major shortcoming as many 3 
cytokines and other catabolic factors (e.g. NO, PGEs) are produced within a degenerate disc 4 
and other cytokines may replace the degenerate effects if one such as IL-1β is removed3, 5.  5 
One alternative would be to inhibit the intracellular signalling mechanisms common to 6 
catabolic processes, however many of these mechanisms are also deployed by the anabolic 7 
factors including growth factors within the disc. Anabolic factors have been proposed as 8 
alternative therapeutic strategies to adjust the balance towards matrix synthesis and of these 9 
GDF-5/6 (CDMP-1/2) appear to be an attractive growth factor17-20 as its receptors are 10 
expressed by NP cells even in degenerate discs however unlike the majority of the growth 11 
factors which have been investigated are not expressed by the blood vessels which are 12 
found in degenerate discs21. It is important to target anabolic factors which do not have off 13 
target effects, such as potential detrimental angiogenesis and accompanied nerve ingrowth 14 
which could result from the use of growth factors whose receptors are also expressed by the 15 
blood vessels in the IVD.  16 
Thus identification of intracellular signalling pathways activated by catabolic factors but not 17 
anabolic factors is essential to identify potential targets to inhibit degeneration without 18 
inhibiting anabolic processes. Recently p38 MAPK (Mitogen activated protein kinase)22, 23 19 
and NFB (Nuclear factor kappa beta)24-27 have been identified within IVD cells, as signal 20 
transduction pathways following IL-1β stimulation and inhibition of these pathways have 21 
shown partial inhibition of the catabolic mediators induced in response to IL-1β22, 23. However 22 
importantly these studies were investigated using IVD cells cultured in monolayer culture 23 
which do not represent the phenotype of NP cells in vivo, indeed very limited studies have 24 
investigated signalling molecule activation in chondrocyte like cells in a 3D culture system 25 
which more closely mimics the in vivo phenotype.  26 
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This study aimed to identify intracellular signalling pathways differentially expressed between 1 
catabolic (IL-1β) and anabolic (GDF-5) factors in human IVDs and determined the activation 2 
status of these pathways in native IVD tissues highlighting potential pathways for new 3 
therapies. 4 
Materials and Methods:  5 
Human IVD samples:  6 
Human IVD tissue was obtained from surgery for micro discectomy or post mortem 7 
examination (processed within 72 hours after death) with informed consent of the patient or 8 
relatives. Ethical approval was obtained from Sheffield Research Ethics Committee 9 
(09/H1308/70). 10 
Histological Grading:  11 
Representative tissue samples were fixed in 10% v/v neutral buffered formalin (Leica, Milton 12 
Keynes, UK) and processed to paraffin wax.  Haematoxylin and eosin stained sections were 13 
evaluated independently by two researchers (AB & CLM) to determine the extent of 14 
degenerative tissue changes. Sections were scored numerically between 0 and 12 based on 15 
the presence of cell clusters, fissures, loss of demarcation and haematoxophilia; a score of 0 16 
to 3 indicates histologically non-degenerate IVDs; ≥4 indicates evidence of degeneration, as 17 
described previously6. 18 
NP cell isolation and culture: 19 
Surgical NP tissue samples were finely minced and digested with 2U/ml protease (Sigma, 20 
Poole, UK) in DMEM (Gibco, Paisley, UK) for 30 minutes at 37°C, followed  by 2mg/mL 21 
collagenase type I (Sigma) in DMEM for 4 hours at 37°C. Cells were maintained in DMEM 22 
supplemented with 10% heat inactivated foetal bovine serum (Gibco), 200U/mL 23 
penicillin/200µg/mL streptomycin (Gibco), 500ng/mL amphotericin B (Sigma), 2mM L-24 
glutamine (Gibco) and 50µg/mL ascorbic acid (Sigma) (complete media). NP cultures were 25 
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used for experimental purposes upto and including passage 2, note no NP samples which 1 
displayed histological evidence of infiltration were used for culture experiments, all cultures 2 
were completed with NP cells from individual patients no pooling of patient samples was 3 
performed. Cultures were maintained at all times at 37°C and 5% CO 2 in a humidified 4 
environment.   5 
Alginate Culture and stimulation regimes 6 
Following expansion in monolayer, NP cells were re-suspended in 1.2%w/v medium 7 
viscosity alginic acid (Sigma) in 0.15M sodium chloride (Fisher Scientific, Loughborough, 8 
UK) at a density of 4.0 x 106 cells/ml (which mimics native NP cell density). Alginate beads 9 
were formed via extrusion through a 19 gauge needle into 200mM CaCl2 (Fisher Scientific), 10 
washed in 0.15M NaCl and media and maintained in complete media for 14 days prior to IL-11 
1β or GDF-5 stimulation with culture media changed twice weekly. To investigate signalling 12 
molecule activation all treatments were performed with either 10ng/ml recombinant IL-1β 13 
(Peprotech, London, UK), 10ng/ml recombinant GDF-5 (Peprotech) or left untreated as 14 
controls. Stimulations were performed for 30 minutes prior to downstream analysis (30 15 
minutes was selected from a preliminary time course experiment where 10,20,30,60 and 180 16 
mins were investigated for NFkB activation (data not shown for time course)). Following 17 
stimulation alginate beads were dissolved in alginate dissolving buffer (55mM C6H6Na2O7 18 
(Sigma); 30mM EDTA (Fisher); 0.15M NaCl; pH 6.0) for 10 minutes at 37°C t o release cells 19 
for downstream analysis with arrays, immunofluorescence or in cell ELISAs.     20 
R&D Proteome Array for intracellular signalling molecules:  21 
NP samples derived from 2 patients (Grade 6, age 21 and 36) were used for this component 22 
of the study (Table S-1). Forty alginate beads were used for each treatment in duplicate. 23 
Following treatment and release from beads, cells were lysed with cell lysis solution 24 
containing protease inhibitors, and protein quantified, activation of 46 signalling molecules 25 
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investigated using the Human Phospho-Kinase Proteome profiler array as per manufactures 1 
instructions (Cat: ARY003; R&D systems, Abingdon, UK).  2 
NFκB Immunocytochemistry 3 
NP samples derived from 3 patients (Age 29,32,36; Grade 6,7,10) were used for this study 4 
(Table S-1) were treated for 30 mins with 10ng/ml IL-1β, 10ng/ml GDF-5 or left untreated as 5 
controls. Following treatment and release from beads cell pellets were fixed in 4% w/v 6 
paraformaldehyde/PBS and cytospins formed spinning 300,000 cells per slide via 1500rpm 7 
30 min cytospin (Shandon cytospin). Cells were washed in tris buffered saline (TBS) for 5 8 
minutes. Non-specific binding sites blocked with 25% v/v goat serum (Abcam) in 1% w/v 9 
BSA in TBS for 1 hour at room temperature. Cells were incubated with rabbit polyclonal 10 
antibody against p65 NFκB (1/50) (Abcam) overnight at 4°C. Cells were washed 3 times for 11 
5 minutes each in 0.1% v/v Tween 20/TBS for 5 minutes, cells were then incubated with 12 
FITC conjugated goat anti-rabbit IgG (1/250) (Abcam) at room temperature for 30 minutes. 13 
Cells were washed 3x5 minutes in 0.1% v/v Tween 20/TBS, mounted in 90% v/v 14 
glycerol/TBS and coverslips sealed with nail varnish. Cells were visualised and images 15 
captured on the Zeiss laser scanning confocal microscope at a magnification of 630X 16 
magnification using the Zen 2009 operating system.  17 
Cell Based ELISAs: ERK1/2, p38 MAPK, IkB, c-Jun: 18 
To confirm results from R&D proteome array on additional patients on key signalling 19 
molecules identified to be upregulated by IL-1β cell based ELISAs were utilised to 20 
investigate quantitative expression of the signalling molecules identified from the array (ERK 21 
1/2, p38 MAPK, c-jun) together with investigating activation of the NFB signalling pathway 22 
which is not included in the array, but demonstrated to be potentially differentially activated 23 
via immunofluorescence. This was investigated by determining levels of phosphorylated IB 24 
which is the first stage in the activation of this signalling pathway. The cell based ELISAs 25 
enable quantification of total and phosphorylated proteins in cells in situ without the need to 26 
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perform protein extraction. A further 3 patients were utilised for this component of the study 1 
(Age 29,32,36; Grade 6,7,10) (Table S-1), Alginate beads were transferred 1 bead per well 2 
of four black 96 well microplates (R&D Systems) in complete media (separate plates were 3 
used for detection of each signalling molecule). Following stimulations beads were 4 
solubilised in alginate dissolving buffer and plates centrifuged for 10 mins 400g to deposit 5 
cells on the base of the culture wells, and fixed in 4% v/v formalin/PBS. The amount of 6 
phosphorylated ERK1/2, p38 MAPK, c-Jun or IκB was measured using cell based ELISA as 7 
per manufactures instructions (R&D systems, UK). The plate was read fluorometrically using 8 
the Tecan Infinite 200 Pro with excitation at 540 nm and emission at 600 nm, then with 9 
excitation at 360 nm and emission at 450 nm. Expression of phosphorylated protein was 10 
then assessed between treatment groups.  11 
Immunohistochemical identification of activation status in vivo 12 
Immunohistochemistry (IHC) was utilised to identify expression levels of phosphorylated-p38 13 
MAPK, phosphorylated-c-jun and phosphorylated-NFB in native NP cells from different 14 
grades of degeneration to investigate activation status in vivo and whether this altered during 15 
degeneration. IHC was utilised rather than western blotting to ensure expression was 16 
quantified only within the native NP cells not any infiltrating cells, in addition IHC has the 17 
advantage that multiple patient samples can be investigated. Expression of each 18 
phosphorylated signalling molecule was investigated in 30 IVD tissue samples (Age: 19 
45.5±14.4) (Table S-1), divided between three study groups: non-degenerate; histologically 20 
graded as intermediate degeneration and histologically graded as severe degeneration. 21 
Briefly, 4μm paraffin sections were dewaxed, rehydrated and endogenous peroxidase 22 
blocked using hydrogen peroxide. After washing in TBS, sections were subjected to heat 23 
induced antigen retrieval (10 minute microwave irradiation in 0.05M tris buffer, pH 9.5). 24 
Following TBS washing, non-specific binding sites were blocked at room temperature (RT) 25 
for 2hrs with 10%v/v normal goat serum in 1%w/v BSA/TBS. Sections were incubated 26 
overnight at 4°C with rabbit polyclonal primary antibodies against human phosphorylated -27 
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p38 MAPK (1:800;Abcam:ab4822), phosphorylated-c-jun (1:400;Abcam:ab32385) and 1 
phosphorylated-NFB (1:100;Abcam:ab31481). Negative controls in which rabbit IgGs 2 
(Abcam) replaced the primary antibody at an equal protein concentration were used. 3 
Following TBS washes, sections were incubated in biotinylated goat anti-rabbit antiserum 4 
(1:300;Abcam) for 30 minutes at RT. Disclosure of secondary antibody binding was by HRP-5 
streptavidin-biotin complex (Vector Laboratories, Peterborough, UK) with 0.08% v/v 6 
hydrogen peroxide in 0.65 mg/mL 3,3'-diaminobenzidine tetrahydrochloride (Sigma) in TBS. 7 
Sections were counterstained with Mayer's Haematoxylin (Leica), dehydrated, cleared and 8 
mounted in Pertex (Leica).  9 
All slides were visualised using an Olympus BX60 microscope and images captured using a 10 
digital camera and software program QCapture Pro v8.0 (MediaCybernetics, Marlow, UK).  11 
Evaluation of IHC was performed by counting 200 NP cells, with immunopositive cells 12 
expressed as a percentage of total count.  13 
Stimulation of NP cells in alginate with IL-1β in presence of signalling inhibitors: 14 
NP samples derived from 3 patients (Age 29,32,36; Grade 6,7,10) (Table S-1), 2 alginate 15 
beads per well were treated with DMSO at equivalent concentrations as those used for 16 
signalling inhibitors or with signalling inhibitors (p38MAPK inhibitor: 40µM SB20358028 17 
(Sigma, Poole, UK); c-jun inhibitor: 800µM c-jun peptide29 (Tocris cat: 1989); JNK inhibitor: 18 
20µm SP60012530 (Sigma); or NFB inhibitor: 10µM Helenalin31 (ENZO, Exeter, UK)) for 1 19 
hr prior to stimulation with 10ng/ml IL-1β for 48hrs or left unstimulated to act as signalling 20 
inhibitor only controls. All treatments were performed in triplicate on each patient 21 
independently. 22 
RNA extraction, cDNA synthesis and Real time PCR: 23 
Following stimulation NP cells were recovered from alginate culture and re-suspended in 24 
0.06%w/v type I collagenase and incubated for 10 minutes at 37°C and cells recovered by 25 
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centrifugation. RNA was extracted using Qiagen RNeasy Mini kit (Qiagen, Crawley, UK) as 1 
per manufacturers' protocol. cDNA was reverse transcribed using Moloney Murine 2 
Leukaemia Virus reverse transcriptase (Bioline) and random hexamers (Applied Biosystems, 3 
Warrington, UK). cDNA samples were interrogated by qRT-PCR for the expression of 4 
MMP3, MMP13, IL-1β, IL-6, IL-8 and aggrecan (Pre-designed primer/probe mixes Applied 5 
Biosystems). Plates were ran on a StepOnePlus real-time PCR machine for 50 cycles 6 
(Applied Biosystems). Relative gene expression levels were calculated using the 2-ΔΔCT 7 
method and normalised against two internal reference genes (GAPDH and 18S) and un-8 
stimulated control samples. Stable expression of internal reference genes was confirmed by 9 
geNorm algorithm. 10 
Statistical Analysis 11 
All data from this study was shown to be non-parametric and as such statistical analysis for 12 
assays was performed using the Kruskal-Wallis test with Conover-Ingman post hoc tests 13 
used to investigate significant differences between treatment groups or grades of 14 
degeneration. All Statistical analysis was performed using statistical software: Stats-Direct. 15 
Results:  16 
Identifying differential signalling pathways between anabolic and catabolic factors: 17 
Proteome profiler arrays were deployed to enable screening of the phosphorylation status of 18 
46 intracellular signalling proteins following stimulation of human NP cells with either IL-1β or 19 
GDF-5 for 30 minutes which was shown from preliminary experiments to be the optimum 20 
time frame. Significant increases in phosphorylated forms of 3 signalling proteins were seen 21 
in cells following stimulation with IL-1β (c-jun, ERK1/2 and p38)(Figure 1, Table 1) and 2 22 
following stimulation with GDF-5 (STAT 1 and 4)(P<0.05)(Table 1). Interestingly IL-1β 23 
stimulation resulted in the significant down regulation of 12 signalling proteins: including 24 
STATs (STAT 3, 5A/B and 6); src family members (src, YES, Fyn, Hck, Lck); and other 25 
signalling proteins involved in focal adhesions (FAK, Paxillin)(Table 1). In addition decreased 26 
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activation of MEK1/2 and mTOR was observed (P<0.05)(Table 1). Whilst GDF-5 only 1 
significantly inhibited 1 signalling protein (Lck) (P<0.05)(Table 1). Of particular interest 2 
pERK1/2 was increased following GDF-5 (6 fold) and IL-1β (30 fold) stimulation although 3 
only significantly so following IL-1β (P<0.05) (Table 1, Figure 1), whilst FAK was down 4 
regulated by both GDF-5 and IL-1β although again only significantly so following IL-1β 5 
stimulation (P<0.05) (Table 1, Figure 1). Surprisingly from the 46 signalling proteins 6 
investigated only three were shown to be differentially activated by IL-1β but not GDF-5, 7 
these were p38 MAPK, JNK and its downstream target c-jun (P<0.05) (Table 1, Figure 1). 8 
Caution should be taken when utilising these results as they were completed on 2 patients 9 
each in quadruplet, thus the biological significance cannot be concluded from this 10 
component of the study. Hence this component of the study was utilised to identify potential 11 
signalling pathways for further investigation in additional patient samples. 12 
As the proteome profiler array did not include NFB signalling this was investigated initially 13 
using immunofluorescence using a phosphorylated antibody which would only detect 14 
activated NFB. NP cells cultured in alginate to maintain NP cell phenotype were stimulated 15 
with IL-1β or GDF-5. Cells which were unstimulated or stimulated with GDF-5 showed 16 
punctate staining only, whilst cells stimulated with IL-1β showed increased staining across 17 
the cell, including nuclear staining, suggesting activation of the NFB pathway was more 18 
pronounced with IL-1 β stimulation (Figure 2). 19 
Cell based ELISAs were then utilised to confirm the results from profiler and 20 
immunofluorescence on further patient samples. Phosphorylated ERK 1/2 was significantly 21 
increased following GDF-5 and IL-1β stimulation although induction was significantly more 22 
following IL-1β stimulation (P<0.05)(Figure 3A). GDF-5 stimulation had no stimulatory effect 23 
on the phosphorylation status of p38 MAPK, c-jun or IB, although a significant decrease 24 
was seen in phosphorylated c-jun (P<0.05)(Figure 3), however IL-1β stimulation induced 25 
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phosphorylation of p38 MAPK, c-jun and IB, which was significant for p38 MAPK and c-jun 1 
(P<0.05)(Figure 3B,C,D). 2 
Activation status of IL-1β induced intracellular signalling pathways in vivo. 3 
To determine whether IL-1β induced signalling pathways: p38 MAPK, c-jun and NFB are 4 
active within human IVDs and whether these are differentially activated within degenerate 5 
discs, human IVDs from differing grades of histological degeneration were investigated for 6 
IHC staining with phosphor specific antibodies. Cytoplasmic staining for phospho-p38 7 
MAPK, c-jun and NFB were identified in NP cells, particularly those cells in clusters (Figure 8 
4). Percentage immunopositive cells for phosphorylated p38 MAPK and phosphorylated 9 
NFB were significantly increased in discs with intermediate histological degeneration 10 
compared to histologically non-degenerate discs (P<0.05)(Figure 4). Whilst percentage 11 
immunopositive cells for phosphorylated c-jun was significantly higher in both high grade and 12 
intermediate grades of histological degeneration compared to histologically non degenerate 13 
discs (P<0.05)(Figure 4). 14 
Effects of inhibitors of intracellular signalling on native mRNA expression in NP cells 15 
Inhibition of p38 MAPK signalling decreased mRNA expression of MMP3, MMP13, IL-1β and 16 
IL-8 but not IL-6 in cells not stimulated with IL-1β although this only reached significance for 17 
MMP3 and IL-1β (P<0.05)(Figure 5). Inhibition of JNK or its downstream target c-jun in the 18 
absence of IL-1β resulted in significant decrease in native mRNA expression of IL-1β 19 
(P<0.05)(Figure 5), whilst only c-jun inhibition decreased native expression of MMP3, and 20 
JNK inhibition decreased native expression of IL-8 (P<0.05)(Figure 5), conversely native IL-6 21 
mRNA expression was increased by inhibition of JNK or c-jun (P<0.05)(Figure 5). Inhibition 22 
of NFB signalling significantly decreased mRNA expression of MMP13 (P<0.05)(Figure 5) 23 
in the absence of IL-1. 24 
Inhibition of IL-1β actions via inhibition of intracellular signalling. 25 
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Real time PCR was utilised to investigate effects of signalling inhibitors on IL-1β actions. IL-1 
1β stimulation of NP cells significantly increased mRNA expression of MMP3, MMP13, IL-2 
1β, IL-6 and IL-8 (P<0.05)(Figure 5).  3 
IL-1β stimulation of NP cells in the presence of a p38 MAPK inhibitor induced MMP3, IL-6 4 
and IL-8 mRNA although to a lesser extent than IL-1β alone (P<0.05)(Figure 5), whilst p38 5 
MAPK inhibition prevented stimulation of MMP13 mRNA by IL-1β but had no effect on the 6 
induction of IL-1β mRNA by IL-1β (Figure 5).  7 
IL-1β stimulation of NP cells in the presence of a c-jun inhibitor induced MMP3, MMP13, and 8 
IL-1β mRNA although to a lesser extent than IL-1β alone (P<0.05)(Figure 5), whilst c-jun 9 
inhibition had no effect on IL-6 or IL-8 mRNA induction by IL-1β (Figure 5). IL-1β stimulation 10 
of NP cells in the presence of a JNK inhibitor induced MMP3, IL-1β and IL-8 mRNA although 11 
to a lesser extent than IL-1β alone (P<0.05)(Figure 5), whilst JNK inhibition had no effect on 12 
MMP13 or IL-6 mRNA induction by IL-1β (Figure 5).  13 
IL-1β stimulation of NP cells in the presence of an inhibitor of NFB signalling inhibited the 14 
IL-1β induced mRNA expression of MMP3, MMP13, IL-1β, IL-6 and IL-8 mRNA expression 15 
(P<0.05)(Figure 5).       16 
Effect of signalling inhibitors on aggrecan mRNA expression. 17 
In order to determine the effect of signalling inhibitors on normal anabolic mRNA expression 18 
the expression of aggrecan was investigated following inhibition of signalling factors. 19 
Inhibition of JNK or c-jun had no effect on mRNA expression of aggrecan, however inhibition 20 
of p38 MAPK or NFB resulted in down regulation of mRNA for aggrecan although this failed 21 
to reach significance (P>0.05)(Figure S-1).  22 
Discussion 23 
This study aimed to investigate the intracellular signalling pathways activated by IL-1β in the 24 
degenerate IVD which were not activated by the anabolic factor GDF-5 to identify potential 25 
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targets for new therapeutic strategies. It is important to identify signalling pathways which 1 
are not activated by anabolic factors such as GDF-5 to ensure native growth factors are not 2 
inhibited, whilst inhibiting catabolic processes. 3 
Initial studies utilised the proteasome arrays to screen 46 signalling molecules to investigate 4 
activation of a wide range of signalling molecules and determine if these signalling 5 
molecules were differentially induced by IL-1β and not by the anabolic factor GDF-5. 6 
Interestingly, only a limited number of signalling molecules were activated by IL-1β in these 7 
cells and of these ERK1/2 was also induced by GDF-5, whilst p38, JNK and c-jun were 8 
induced significantly more by IL-1β than GDF-5, whilst this component of the study was 9 
completed on two patients. These results were further confirmed in additional patients using 10 
cell based ELISAs. IL-1β has been previously shown to induce expression of 11 
phosphorylated-ERK, p38 and JNK in human IVD cells in monolayer culture32, and together 12 
with NFB signalling in rat NP cells33. Furthermore as NFB signalling was not included 13 
within the array, but previous studies have demonstrated this is a key signalling pathway 14 
activated by IL-1β in IVD cells24-27, this was investigated within human NP cells cultured in 15 
alginate to maintain phenotype which demonstrated activation by IL-1β but not GDF-5, which 16 
was demonstrated using immunofluorescence and confirmed by cell based ELISAs. 17 
Unfortunately performing these experimental procedures in alginate beads to maintain the 18 
phenotype of the NP cells, alginate was shown to have high auto-fluorescence within 19 
immunofluorescence experiments which prevented quantification of this data, however the 20 
use of cell based ELISAs confirmed activation of the NFB signalling pathway.  21 
GDF-5 stimulation resulted in activation of STAT 1 and 4 which has not been previously 22 
demonstrated, however STAT 1 has been shown to be involved in the signalling of other 23 
growth factors in chondrocytes, and has been shown to be a key signalling molecule in FGF 24 
signalling34, and IGFBP-3 signalling35. 25 
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Interestingly IL-1β stimulation resulted in the down regulation of 12 signalling proteins: 1 
including STATs (STAT 3, 5A/B and 6), STAT3 has been shown to be expressed by human 2 
NP cells previously36, STAT3 is associated with IL-6 signalling in chondrocytes where it has 3 
been shown to induce expression of cartilage matrix genes37. These anabolic effects of IL-6 4 
were inhibited by STAT3 knockdown37. Thus the down regulation of STAT3 by IL-1β seen in 5 
the current study could be linked to the effects of IL-1 on matrix gene expression, however 6 
its role in the IVD is poorly understood and requires further investigation.  7 
The combined down regulation of the src family proteins, FAK and Paxillin demonstrate a 8 
potential role for IL-1β in the disruption of focal adhesion signalling, src family protein 9 
kinases phosphorylate FAK and if these are inhibited integrin regulated adhesion to the 10 
extracellular matrix is disrupted38. Thus the inhibition of src family, FAK and paxillin signalling 11 
could explain the altered integrin signalling seen during disc degeneration39.  12 
mTOR is a key signalling pathway involved in autophagy, inhibition of the mTOR complex 13 
has been demonstrated to induce autophagy40, thus the inhibition of mTOR shown here by 14 
IL-1β could provide a role for IL-1β induced autophagy in the IVD40. Additionally mTOR is 15 
involved in regulation of cellular senescence and inhibitors of mTOR have been shown to 16 
induce cellular senescence40, which is also a key feature of disc degeneration41. As such the 17 
modulation of these signalling pathways by IL-1β requires further investigation particularly 18 
whether abrogating the inhibition can be targeted by potential therapies.   19 
It should be noted that activation of these signalling molecules reported within this study 20 
were completed following 30 minutes, which was shown to be optimal from initial preliminary 21 
studies, it was not possible to complete all studies at multiple time points but it should be 22 
considered that as arrays investigated a wide range of signalling molecules further factors 23 
may be activated by these factors at alternative times, however the majority of studies 24 
investigating signalling factors do so over short time periods such as 30 mins. 25 
16 
 
Following the identification of p38, c-jun and NFB signalling as potentially differentially 1 
induced by IL-1β, expression of phosphorylated forms of these proteins was determined in 2 
native human IVDs, which demonstrated all three signalling proteins were active within 3 
native NP cells with increased expression of phosphorylated-p38, c-jun and NFB in discs 4 
with intermediate grades of histological degeneration compared to those discs graded as 5 
non-degenerate, whilst c-jun was also increased in discs with severe histological 6 
degeneration. Interestingly the discs with highest levels of expression are also those which 7 
have previously been shown to express highest levels of IL-1β i.e. discs with intermediate 8 
grades of degeneration6. Tolonen et al., previously investigated protein expression of c-jun in 9 
human IVD samples and demonstrated expression in 74% of patient samples investigated42, 10 
unfortunately it is not clear whether they utilised a phospho-specific antibody and they did 11 
not investigate whether expression altered during degeneration, however in agreement with 12 
the current study expression was seen within NP cell clusters42. Interestingly in stab induced 13 
degeneration in rat IVDs an induction of p-ERK and p-p38 was observed associated with 14 
increased immunopositivitiy for IL-1β and IL-6, in contrast no increase in p-JNK was 15 
observed43. Nerlich et al., also demonstrated increased activation of NFB signalling in 16 
human IVDs which increased with age and grade of degeneration44. Increased NFB 17 
signalling with degeneration has been further confirmed recently45. Together this data 18 
supports the potential role of inhibitors of these signalling pathways in IVD degeneration.  19 
Thus, this study went on to investigate the potential use of inhibitors of these signalling 20 
pathways within human NP cells derived from degenerate discs on a number of key targets 21 
which have been shown previously to be regulated by IL-1β. Interestingly inhibitors of p38 22 
signalling and the JNK/c-jun pathway only partially abrogated effects of IL-1β suggesting 23 
these factors alone may not be sufficient to inhibit the plethora of effects induced by IL-1β 24 
(Figure S-2). Klawitter et al., demonstrated partial inhibition of IL-1β effects via curcuma and 25 
curcumin with inhibition of IL-1β induced expression of MMPs and IL-6 but failed to inhibit 26 
effects on IL-1β, IL-8 and TNF expression, these effects were shown to be a result of JNK 27 
17 
 
inhibition32, whilst other studies have suggested curcumins actions are via inhibition of NFB 1 
signalling25, 46, 47. Yu et al., demonstrated abrogation of IL-1 induced inhibition of Sox9 and 2 
collagen type II expression by curcumin46. Further to this, Ma et al., recently demonstrated 3 
curcumin could reduce degenerative changes in a rat degeneration model25, both studies 4 
associating actions to inhibition of the NFB pathway. Inhibition of p38 signalling in rabbit NP 5 
cells abrogated the effects of IL-1 on inhibition of matrix synthesis and partly reduced the 6 
effects on expression of Cox-2, MMP3, IL-1 and IL-623 and PGE222 which agrees with the 7 
current study.  8 
However inhibition of the NFB signalling pathway demonstrated the most potential in the 9 
current study with abrogation of all the effects of IL-1β investigated. Wang et al., also found 10 
that NFB inhibition could completely abrogate IL-1β induced MMP3, whilst inhibition of 11 
p38/ERK/JNK only partially abrogated the effects of IL-1β28. In contrast IL-1β induced 12 
expression of ADAMTS4 could be blocked by inhibitors of NFB, p38, JNK and ERK1 13 
signalling33, recently Sun et al., further demonstrated the important role for NFB signalling 14 
in the IL-1β induced expression of ADAMTS24, 45. Inhibition of NFB signalling has been 15 
shown to abrogate a wide range of IL-1 induced effects, demonstrating the potential of this 16 
signalling target for inhibiting the plethora of IL-1 effects in the IVD26. The potential role of 17 
NFB as a target for treating disc degeneration is further supported by the finding that NFB 18 
signalling was increased in an accelerated aging mouse model, and catabolic effects could 19 
be blocked by inhibiting NFB48. However, the current study demonstrated inhibition of the 20 
NFB signalling did induce a baseline decrease in the expression of aggrecan mRNA 21 
expression, which although failed to reach significance should be treated with caution.  22 
Conclusion 23 
This study has highlighted three key pathways were identified which were differentially 24 
activated by IL-1β but not GDF-5; namely p38, c-jun and NFB. All pathways were shown to 25 
be activated during human IVD degeneration and inhibition of these pathways reduced or 26 
18 
 
abrogated the catabolic effects of IL-1β, with inhibition of NFB signalling demonstrating 1 
more widespread inhibition of IL-1 effects and thus potentially holds most promise for future 2 
investigations (Figure S-2).  3 
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Figure legends: 1 
Figure 1: Proteasome kinase array for 46 intracellular signalling molecules. Representative 2 
arrays shown for control (A), IL-1β (B) and GDF-5 (C) stimulated human NP cells. D: Box 3 
and whisker plots shown for key kinases/transcription factor (ERK1/2 (Red); FAK (Blue); p38 4 
MAPK (Green); JNK (Purple) and c-jun (Orange)) indicated on the representative images 5 
with matching colour boxes, colours indicated on legend for graph. Box and whisker plots 6 
show relative protein expression normalised to untreated controls in 2 patients each 7 
stimulated in duplicate and tested on arrays in duplicate. Significant differences between 8 
treatment groups shown with line above box and whiskers (P<0.05). 9 
Figure 2: Representative images for p65-NFB immunofluorescence from human NP cells 10 
cultured in alginate and stimulated with IL-1β (B) and GDF-5 (C) or unstimulated controls 11 
(A). Human NP cells from 3 patients cultured in alginate and treated in triplicate with IL-1β 12 
and GDF-5 or unstimulated controls. 13 
Figure 3: Cell based ELISAs for demonstrating relative phosphorylated ERK1/2 (A), p38 14 
MAPK (B), c-jun (C) and IB (D) protein expression normalised to untreated controls. Human 15 
NP cells from 3 patients cultured in alginate and treated in triplicate with IL-1β and GDF-5 or 16 
unstimulated controls. Statistical differences between groups demonstrated by bars and 17 
*=P<0.05. 18 
Figure 4: Immunohistochemical analysis for phosphorylated p38 MAPK (A-D); c-jun (E-H) 19 
and NFB (I-L) in human IVD discs. Representative images of immunohistochemical staining 20 
demonstrated for low grade degenerate discs (A,E,I); Intermediate grade discs (B,F,J); high 21 
grade discs (C,G,K). Percentage immunopositivty within NP cells with differing grades of 22 
degeneration (D,H,L). Statistical differences between immunopositivity for phosphorylated 23 
signalling molecules in intermediate grades of degeneration (4-6) or severe degeneration 24 
(≥7), compared to non degenerate discs (≤3) shown with *=P<0.05. (n=30). 25 
25 
 
Figure 5: Relative mRNA expression for MMP3 (A), MMP13 (B), IL-1β (C), IL-6 (D) and IL-8 1 
(E) normalised to housekeeping genes (GAPDH and 18s) and untreated control cells. Data 2 
shown generated from NP cells sourced from three independent patients cultured in alginate 3 
and treated with or without IL-1β, with or without prior treatment with inhibitors of signalling 4 
molecules (p38 MAPK; c-jun, JNK and NFB), all treatments performed in triplicate within 5 
each patient sample. * = significant difference between treated cells compared to untreated 6 
controls (P<0.05); ^ = significant difference between IL-1β stimulated cells following prior 7 
treatment with signalling inhibitors compared to stimulation with IL-1β alone P<0.05. 8 
 9 
Figure S - 1: Relative mRNA expression for aggrecan normalised to housekeeping genes 10 
(GAPDH and 18s) and untreated control cells. Data shown generated from NP cells sourced 11 
from three independent patients cultured in alginate and treated with or without signalling 12 
inhibitors. All treatments performed in triplicate within each patient sample. 13 
26 
 
Figure S - 2: Schematic representing key findings.  1 
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